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Local administration of glucocorticoids decreases
synovial citrullination in rheumatoid arthritis
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Abstract
Introduction: Protein citrullination is present in the rheumatoid synovium, presumably contributing to the
perpetuation of chronic inflammation, in the presence of specific autoimmunity. As a result, the present study
examined the possibility that effective antirheumatic treatment will decrease the level of synovial citrullination.
Methods: Synovial biopsies were obtained from 11 rheumatoid arthritis (RA) patients before and after 8 weeks of
treatment with 20 mg methotrexate weekly, 15 RA patients before and 2 weeks after an intraarticular
glucocorticoid injection, and eight healthy volunteers. Synovial inflammation was assessed with double-blind
semiquantitative analysis of lining thickness, cell infiltration, and vascularity by using a 4-point scale. Expression of
citrullinated proteins (CPs) with the monoclonal antibody F95 and peptidylarginine deiminase (PAD) 2 and 4 was
assessed immunohistochemically with double-blind semiquantitative analysis. In vitro synovial fluid (SF), peripheral
blood (PB), mononuclear cells (MCs), and synovial explants obtained from RA patients were incubated with
dexamethasone and analyzed with immunohistochemistry for expression of CP as well as PAD2 and PAD4
enzymes.
Results: The presence of synovial CP was almost exclusive in RA compared with healthy synovium and correlated
with the degree of local inflammation. Treatment with glucocorticoids but not methotrexate alters expression of
synovial CP and PAD enzymes, in parallel with a decrease of synovial inflammation. Ex vivo and in vitro studies
suggest also a direct effect of glucocorticoids on citrullination, as demonstrated by the decrease in the level of
citrullination and PAD expression after incubation of SFMC and synovial explants with dexamethasone.
Conclusion: Synovial citrullination and PAD expression are dependent on local inflammation and targeted by
glucocorticoids.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease characterized by the presence of highly specific
anti-citrullinated protein antibodies (ACPAs) [1]. These
antibodies recognize several different proteins that are
citrullinated. Citrullination is the conversion of peptidy-
larginine to peptidylcitrulline through a calcium-depen-
dent process catalyzed by the peptidylarginine deiminase
(PAD) enzymes. Five PAD isotypes have been described
in humans (PAD1, PAD2, PAD3, PAD4, and PAD6),
which are expressed in a variety of tissues, but only
PAD2 and PAD4 have been found to be expressed in
inflamed synovial tissue of RA and other inflammatory
arthritides [2].
Despite the high specificity of ACPA in RA in com-
parison to other arthritides and other inflammatory dis-
eases [3], the presence of CP is not restricted to RA
synovial tissue [4,5], but rather associated with inflam-
mation in general [6]. Synovial citrullination appears
therefore not to be essential for the predisease phase of
induction of specific anti-citrulline immunity. Conver-
sely, protein citrullination enhances the HLA binding
capacity of synovial-derived proteins and promotes NF-
B and tumor necrosis factor (TNF) production in the
presence ACPA [7]. This suggests that local synovial
citrullination might be essential in a later phase of the
disease process, contributing to occurrence and perpe-
tuation of chronic synovitis in the presence of specific
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anti-citrulline antibodies. It is therefore conceivable that
downregulation of synovial citrullination by any means
will contribute to the resolution of local inflammation.
We hypothesize that effective antirheumatic treatment
with either antiinflammatory, intraarticular glucocorti-
coids (GCs), or a disease-modifying antirheumatic drug,
such as methotrexate (MTX) will decrease synovial
citrullination in vivo. As a result, the present study
aimed to investigate any direct effect of these drugs on
protein citrullination.
Materials and methods
Patients
Twenty-six patients meeting the 1987 American Col-
lege of Rheumatology criteria for RA [8] were recruited
for this study. In a first group, 11 patients (six women
and five men; median age, 56 years; range, 33 to 78
years) with newly diagnosed RA (symptom duration
less than 1 year) previously disease-modifying anti-
rheumatic drug (DMARD) naïve were started on MTX,
10 mg weekly, and reached a stable dose of 20 mg
after 2 weeks, increasing the dose with 5 mg every
week. Synovial biopsy samples were obtained by
arthroscopy from all patients before and after a median
of 8 weeks of treatment. Clinical evaluation of the
therapeutic response according to EULAR response
criteria was performed a median of 3 months after
methotrexate initiation. In a second group, 15 RA
patients (11 women and four men; median age, 63
years; range, 34 to 83 years) with active knee arthritis
independent of disease duration received an intraarti-
cular injection of 40 mg of triamcinolone hexaceto-
nide, and synovial biopsy samples were obtained with
arthroscopy before and after 2 weeks after intraarticu-
lar treatment. In this second group, associated
DMARD treatments were stable for at least 2 weeks
before initiation of treatment and throughout the
entire study period. Clinical evaluation of the thera-
peutic response was performed with macroscopic scor-
ing of the level of inflammation during arthroscopy.
Nonsteroidal antiinflammatory drugs and per-oral pre-
dnisolone to a maximum dose of 10 mg daily were
permitted in both groups. Additionally, synovial biopsy
samples were obtained with arthroscopy in eight
healthy volunteers. All procedures were approved by
the Northern Stockholm Ethical Review Board, and
informed consent was obtained from all the partici-
pants in the study.
Synovial biopsies handling
Synovial biopsy samples were snap-frozen during arthro-
scopy in dry-ice cooled isopentane. Serial cryostat sec-
tions (7 μm) were fixed for 20 minutes with 2% (vol/vol)
formaldehyde and stored at -70°C.
Cell culturing
Paired peripheral blood mononuclear cells (PBMCs) and
synovial fluid mononuclear cells (SFMCs) from RA
patients (n = 6) were cultured as duplicates in RPMI 1640
supplemented with 20% heat-inactivated fetal bovine
serum (FBS), 2 mM L-glutamine, 50 IU/ml penicillin, and
50 μg/ml streptomycin (Gibco, Carlsbad, CA, USA) and
incubated at 37°C with 5% CO2 in a humidified atmo-
sphere. Cells were grown at a density of 1 × 106 per ml in
polypropylene tubes and incubated with dexamethasone
for 24 hours at a final concentration of 1 and 100 μM
DXM. After treatment, cells were washed, resuspended in
PBS, and seeded on glass slides (Thermo Scientific diag-
nostic microscopic glass slides, Braunschweig, Germany).
Adherent cells were fixed for 20 minutes at 4°C with 2%
(vol/vol) formaldehyde (Merck, Darmstadt, Germany).
Synovial explants
Synovial tissue pieces obtained from an orthopedic hip-
replacement surgery in an RA patient were selected
based on maximal macroscopic score of inflammation,
dissected and seeded on 24-well plates in RPMI, supple-
mented with 10% heat-inactivated fetal calf serum
(FCS), 2 mM L-glutamine, 50 IU/ml penicillin, and 50
μg/ml streptomycin (Gibco), and incubated at 37°C with
5% CO2 in a humidified atmosphere for 24 hours with
100 μM DXM. Tissue pieces were then transferred to
six-well plates and cultured for additional 5 days with
fresh prepared serum supplemented with the same con-
centrations of the drugs. At the end of the incubation,
medium was removed, and tissue pieces were cryosec-
tioned, fixed for 20 minutes at 4°C with 2% (vol/vol) for-
maldehyde (Merck), and stored at -80°C.
Immunohistochemistry and histologic evaluation
Presence of citrullinated proteins (CPs) was detected by
using a mouse IgM monoclonal antibody (F95), which
was raised against a decacitrullinated peptide linked to
the carrier protein, keyhole limpet hemocyanin [9-11].
For detection of PAD enzyme expression, we used two
PAD4 (SN823 and SG1467) [12,13] and one PAD2
(SN665) [12] rabbit polyclonal antibodies and one addi-
tional rabbit polyclonal antibody (ROI002) (CosmoBio,
Tokyo, Japan) to identify PAD2 expression [14]. Appro-
priate negative controls were used for each antibody.
Two independent observers (DM and AIC), who were
unaware of the sample’s identity, scored the presence of
CP and PAD enzymes in synovial tissue by using a 4-
point scale (0, no staining; 1, low amounts of staining; 2,
moderate amounts of staining; 3, high amounts of stain-
ing). In parallel, histologic scoring of the degree of
inflammation was performed, by using a 4-point scale,
by double-blind semiquantitative analysis (DM and SR)
of the lining thickness, infiltration level, and vascularity
Makrygiannakis et al. Arthritis Research & Therapy 2012, 14:R20
http://arthritis-research.com/content/14/1/R20
Page 2 of 9
in serial hematoxylin eosin staining. In every instance,
the final scores represent the mean of the two observa-
tions. The presence of CP and PAD enzymes in SFMCs
and PBMCs was assessed with manual counting of posi-
tive cells and expressed as a percentage of positive cells
in the total number of the cells.
Statistical analysis
Statistical analysis was performed by using the Wilcoxon
test for comparison of paired samples, the Mann-Whit-
ney test for comparison of independent samples, and
the Spearmen rank correlation test. All comparisons
were planned, and therefore, no Bonferroni correction
was applied. Differences between proportions were ana-
lyzed with the Fisher Exact test. In vitro experiments
results were analyzed by using one-way (ANOVA) ana-
lysis of variance, as appropriate. P values less than 0.05
were considered statistically significant.
Results
Intracellular but not extracellular presence of citrullinated
peptides is RA specific
It was previously suggested that the intracellular pattern
of F95 staining is a specific trait of RA as compared
with healthy synovium [11]. Further to investigate this,
we analyzed the immunohistochemical expression of
citrullinated peptides (as detected by F95 antibody) and
the PAD2 and PAD4 enzymes in baseline RA samples
obtained before initiation of treatment, as compared
with healthy synovial biopsies. Intracellular F95 staining
was readily detected in RA samples (24 of 28, 85.7%)
and absent in healthy synovium (none of eight; P <
0.05). Extracellular F95 staining was present in RA (24
of 28, 85.7%) and to a lesser extent in healthy synovial
tissue (one of eight, 12.5%; P < 0.05). PAD2 and PAD4
expression was detected in all baseline RA samples
(100%) and a vast majority of the healthy synovial biop-
sies (seven of eight, 87.5% positive for ROI002 antibody;
six of eight, 75% positive for SN665 antibody; all eight,
100% positive for SG1467 antibody, and seven of eight,
87.5% positive for SN8233 antibody) and with a general
higher expression of all investigated molecules in RA as
compared with healthy synovium (Figure 1; P < 0.05 for
all investigated antibodies).
Synovial citrullination and PAD expression correlate with
the degree of inflammation
To investigate further the relation between inflammation
and citrullination, we analyzed the correlation between
the presence of total and intracellular CP, as well as
PAD enzymes, and the degree of local inflammation in
baseline samples obtained from all RA patients and
healthy individuals (n = 34). As expected, most of the
investigated markers correlated with the degree of lining
thickness, cell infiltration, and vascularity (Table 1).
Intraarticular GC, but not MTX, decreases synovial
citrullination and PAD4 expression
The observed correlation between inflammation and
citrullination prompted us to investigate the effect of
antirheumatic treatment on synovial citrullination and
PAD expression.
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Figure 1 Representative picture showing that expression of intracellular and total citrullinated protein (CP), as well as PAD2 and
PAD4 enzymes, is higher in rheumatoid arthritis (RA; upper panel) as compared with healthy (lower panel) synovial tissue. Frozen
synovial biopsy sections show diaminobenzidine (brown) immunoperoxidase staining (hematoxylin counterstained) for citrullinated proteins and
peptidylarginine deiminase (PAD) enzymes detected with the F95 antibody, anti-PAD2 (with two different antibodies, ROI002 and SN665), and
PAD4 (with two different antibodies, SN823 and SG1467) antibodies (original magnification, ×100). Insets show close-up details from the same
samples.
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Local administration of GC significantly decreased
both total and intracellular expression of CP from a
median score of 2 (range, 0 to 3) to a median score of 1
(range, 0 to 2), P < 0.05. PAD4 expression also
decreased after treatment from a median score of 2
(range, 1 to 3) to a median score of 1 (range, 0 to 2.5),
P < 0.05, when evaluated with the SG1467 antibody and
to a lesser extent when evaluated with the SN823 anti-
body (P = 0.06), whereas no changes were observed for
PAD2 expression after intraarticular administration of
GCs (Figure 2). The GC effect on citrullination and
PAD expression was paralleled by a significant decrease
(P < 0.05) in the lining thickness (from a median score
of 1, range, 0 to 2, to a median score of 0.5, range, 0 to
1) and cell infiltration (from a median score of 3, range,
2 to 3, to a median score of 2, range, 1 to 3), but not
vascularity. All patients were good clinical responders,
as evaluated with macroscopic investigation of the joint
inflammation at the time of arthroscopy and retrospec-
tive scoring of photo records.
In contrast, methotrexate treatment had no effect on
either synovial inflammation or local expression of CP
and PAD (Figure 3), despite a good clinical response in
nine of 11 treated patients with a significant decrease in
the DAS28 score from a mean ± SEM of 5.5 ± 0.3 to a
mean ± SEM of 3.4 ± 0.4 after 3 months of treatment.
Interestingly, the same was true when only EULAR
responders (n = 9) were included in the analysis.
In vitro GCs have a direct effect on cellular expression of
CP, potentially through a PAD-dependent mechanism
Apart from their inflammation-damping effect, GCs may
also directly target the process of citrullination. To inves-
tigate this, we tested the effect of DXM on CP and PAD
enzymes expression in vitro in SFMC and PBMC paired
samples of RA individuals. Confirming our in vivo results,
DXM decreased the expression of CP, PAD4, but also
PAD2, in SFMC (Figure 4) but not PBMC (data not
shown). The effect of DXM is dose dependent and pre-
sent at doses as low as 1 μM (Figure 5). No such effects
were observed for methotrexate when tested in the same
systems (Additional file 1).
GC effect can be reproduced ex vivo in synovial explants
biopsies
SFMCs are in vitro surrogate replacements of the syno-
vial biopsy complex milieu, although lacking important
characteristics, such as the local complex intracellular
interplay. To circumvent this caveat, we established
explants from a synovial biopsy obtained from an RA
patient at open surgery for hip replacement and tested
the effect of GCs to confirm our results further. DXM
treatment of the explants decreased the expression of CP
and PAD4 but not PAD2, whereas parallel histologic
investigation did not reveal major changes in the histolo-
gic composition of the samples. Once again, no such
effects were observed for methotrexate (Additional file 2).
Discussion
Protein modification through posttranslational citrullina-
tion in the rheumatoid joint is thought to play an impor-
tant role in perpetuation of local chronic inflammation in
the presence of specific anticitrulline immunity. This is
the first report showing that synovial citrullination is
actively modulated by antirheumatic treatment.
Previous studies characterized synovial expression of
citrullination, showing a general increase in the level of
citrullination in the presence of active inflammation
[2,4-6,11,15]. These early reports used one particular
method for detection of citrullination, consisting of the
chemical modification of the citrullinated tissue proteins
to allow their recognition by an antibody raised against
similarly modified citrullinated proteins [16]. However,
this technique is no longer available, and in our hands, the
only other antibody performing well in immunohisto-
chemistry is F95 [10]. As with the modified anti-citrulline
antibody, F95 is supposed to recognize a large array of
citrullinated molecules independent of the amino acid
context. We previously demonstrated that this antibody is
able to recognize specifically at least one RA-relevant
citrullinated antigen, citrullinated fibrinogen [17]. How-
ever, a somewhat more restricted pattern of citrullination,
as compared with the modified anti-citrulline antibodies,
has been observed both in synovial biopsies [11] and in
other tissues, such as lungs of smoking healthy individuals
[18]. By using this new antibody, De Rycke et al. [11] were
able to describe an RA-specific intracellular F95 staining.
We confirm this finding by the virtually absence of F95-
positive cells in synovial biopsies of healthy individuals.
Only few reports of PAD synovial expression are cur-
rently available [2,11,19]. The most thorough investiga-
tion of synovial PAD expression was performed by
Foulquier et al. [2], showing correlation between expres-
sion of both PAD2 and PAD4 expression with the
degree of synovial inflammation. We confirm these find-
ings and identify the same correlation for the CP
expression.
Table 1 Correlations between CP, PAD2, and PAD4
expression and synovial inflammation
Mean lining thickness Infiltration Vascularity
Total CP 0.4 (< 0.05) 0.5 (< 0.001) 0.6 (< 0.001)
Intracellular CP 0.4 (< 0.05) 0.4 (0.001) 0.6 (< 0.01)
PAD2 (ROI002) 0.5 (< 0.05) 0.6 (< 0.001) 0.4 (< 0.05)
PAD2 (SN665) 0.6 (< 0.001) 0.7 (< 0.001) 0.5 (< 0.01)
PAD4 (SG1467) 0.6 (< 0.01) 0.3 (NS) 0.3 (NS)
PAD4 (SN823) 0.5 (< 0.01) 0.1 (NS) 0.2 (NS)
Values are expressed as Spearman rank correlation coefficients (P values). CP,
citrullinated protein; NS, not significant.
Makrygiannakis et al. Arthritis Research & Therapy 2012, 14:R20
http://arthritis-research.com/content/14/1/R20
Page 4 of 9
Before GC After GC 
HTX-EOS 
F95 
PAD2 
ROI002 
PAD2 
SN665 
PAD4 
SN823 
PAD4 
SG1467 
GC before GC after
0
1
2
3
4
F9
5 
in
tr
ac
el
lu
la
r
GC before GC after
0
1
2
3
4
PA
D
2 
R
O
I0
02
GC before GC after
0
1
2
3
4
PA
D
2 
SN
66
5
GC before GC after
0
1
2
3
4
PA
D
4 
SN
82
3
GC before GC after
0
1
2
3
4
PA
D
4 
SG
14
67
A. B. 
C. D. 
E. 
F. G. 
H. 
I. J. 
K. 
L. M. 
N. 
O. P. 
Q. 
* 
* 
Figure 2 Intraarticular glucocorticoid (GC) treatment of rheumatoid arthritis (RA) patients (n = 15) decreases synovial expression of
F95 and peptidylarginine deiminase 4 (PAD4) but not PAD2. Hematoxylin-eosin (HTX-EOS) staining illustrates the histologic pattern of
frozen synovial biopsy sections of an RA patient before (a) and after (b) intraarticular GC treatment. Brown diaminobenzidine immunoperoxidase
staining shows a significant decrease in the expression of citrullinated proteins, as detected by F95 antibody (c, before treatment; d, after
treatment), no changes in PAD2 expression as detected by either ROI001 (f, before treatment; g, after treatment) antibody or SN665 antibody (i,
before treatment; j, after treatment) and a significant decrease in PAD4 expression, as detected by SG1467 antibody (o, before treatment; p, after
treatment) but not by SN823 antibody (l, before treatment; m, after treatment). Original magnification, ×100; insets show close-up details from
the same samples. Graphs show results of semiquantitative analysis on a 4-grade scale for citrullinated proteins (e), PAD2 as detected with either
ROI001 (h) or SN665 (k) antibody, and PAD4 as detected with either SN823 (n) or SG1467 (q) antibody. Values represent the median, and
whiskers, the range (*P < 0.05).
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Figure 3 Methotrexate (MTX) treatment of rheumatoid arthritis (RA) patients (n = 11) does not modulate synovial expression of either
citrullinated proteins or PAD2 and PAD4 enzymes. Hematoxylin-eosin (HTX-EOS) staining illustrates the histologic pattern of frozen synovial
biopsy sections of an RA patient before (a) and after (b) MTX treatment. Brown diaminobenzidine immunoperoxidase staining shows no
changes in expression of citrullinated proteins as detected by F95 antibody (c, before treatment; d, after treatment), PAD2 as detected with
either ROI001 antibody (f, before treatment; g, after treatment), or SN665 antibody (i, before treatment; j, after treatment) and PAD4 as detected
with either SN823 antibody (l, before treatment; m, after treatment), or SG1467 antibody (o, before treatment; p, after treatment). Original
magnification ×100, whereas insets show close-up details from the same samples. Graphs show results of semiquantitative analysis on a 4-grade
scale for citrullinated proteins (e), PAD2 as detected with either ROI001 (h) or SN665 (k) antibody, and PAD4 as detected with either SN823 (n)
or SG1467 (q) antibody. Values represent the median, and whiskers, the range (*P < 0.05).
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The novel finding of the current study is the reduction
in citrullination and PAD expression induced by intraar-
ticular GC, which was not observed after MTX treat-
ment. One potential explanation for this difference is
the different time points to obtain the follow-up biopsy,
2 weeks after treatment initiation with GCs, as com-
pared with 8 weeks for MTX. However, the two differ-
ent time points were chosen in accordance with the
clinical expectation of maximal effect of the adminis-
tered drug, which would theoretically increase the
chance to observe a change, not only for GCs, but also
for MTX. We were able also to demonstrate a direct
effect of GCs independent of inflammation in our syno-
vial explants. This is further supported by the results of
the in vitro experiments, in which we observed a dose-
dependent effect of GCs despite obvious difficulties in
standardization of a quantitative analysis by using
immunohistochemistry on cells. Interestingly, although
GCs decreased citrullination and PAD4 expression in
SFMCs, no such effect was observed in PBMCs. This
could be due to the lower baseline levels and, as a con-
sequence, to the lower sensitivity to detect changes of
expression of the investigated molecules in PBMCs as
compared with SFMCs. Conversely, it could be due to
different regulatory mechanisms and cellular activation
states of PBMCs, as compared with SFMCs, as pre-
viously suggested [20]. Despite major advances in under-
standing the central role of citrullination and anti-
citrulline immunity in RA pathogenesis, we face a strik-
ing lack of knowledge regarding regulatory factors
responsible for induction, perpetuation, and/or ameli-
oration of the process of citrullination, both locally in
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Figure 4 Dexamethasone (DXM) decreases the expression of citrullinated proteins and PAD4 and PAD2 in synovial fluid mononuclear
cells (SFMCs), in a dose-dependent manner. Brown diaminobenzidine immunoperoxidase staining detects citrullinated proteins, as detected
with F95 antibody, PAD2 as detected with ROI001 antibody, and PAD4 as detected with SN823 antibody. Original magnification, ×100. Graphs
show results of manual counting in six different SFMC samples analyzed in duplicate, and results are expressed as fold decrease of the number
of positive cells in the treated samples as compared with controls.
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the joint and even more generally in other tissues where
citrullination occurs either under physiologic (skin) [21]
or pathologic conditions (lungs of smokers) [18,22]. It is
generally accepted that citrullination accompanies
inflammation, and it has been suggested that induction
of citrullination by inflammatory stimuli such as TNF
occurs after PAD4 activation and induction of signaling
pathways dependent on NF-B [23]. Interestingly, the
antiinflammatory effects of GCs are at least partially
dependent on NF-B, as demonstrated by their lack of
effect in animal models of acute inflammation in NF-B
knockout mice [24]. In contrast, MTX appears to have
limited effects on NF-B activation, as demonstrated by
high levels of activation in PBMCs of MTX-treated RA
patients that can be reversed by anti-TNF agents [25].
These findings suggest that GCs might affect citrullina-
tion through PAD4 downregulation through an NF-B-
dependent mechanism.
Conclusion
The inflamed RA synovium is characterized by high
expression of intracellular CP and PAD4 enzyme that is
reversed through GCs, but not MTX treatment. Further
investigation of the exact mechanism of action and
comparison with other antirheumatic drugs is
warranted.
Additional material
Additional file 1: Methotrexate (MTX) has no effect on expression
of citrullinated proteins and PAD4 and PAD2 in SFMCs. Brown
diaminobenzidine immunoperoxidase staining detects citrullinated
proteins, as detected with F95 antibody, PAD2 as detected with ROI001
antibody, and PAD4 as detected with SN823 antibody. Original
magnification, ×200. Graphs show results of manual counting in six
different SFMC samples analyzed in duplicate, and results are expressed
as fold decrease of the number of positive cells in the treated samples as
compared with controls.
Additional file 2: MTX has no effect on expression of citrullinated
proteins and PAD4 expression in an RA synovial explant. Brown
diaminobenzidine immunoperoxidase staining shows citrullinated
proteins as detected with F95 antibody, PAD2 as detected with ROI001
antibody, and PAD4 as detected with SN823 antibody. Original
magnification, ×250.
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